Freedman MS, et al. Moving toward earlier treatment of multiple sclerosis: Findings from a decade of clinical trials and implications for clinical practice. Mult Scler Relat Disord. 2014;3(2):147–55.

Article  PubMed  Google Scholar 

Solomon AJ, Corboy JR. The tension between early diagnosis and misdiagnosis of multiple sclerosis. Nat Rev Neurol. 2017;13(9):567–72.

Article  PubMed  Google Scholar 

Zalc B. One hundred and fifty years ago Charcot reported multiple sclerosis as a new neurological disease. Brain. 2018;141(12):3482–8.

Article  PubMed  PubMed Central  Google Scholar 

Kaisey M, et al. Incidence of multiple sclerosis misdiagnosis in referrals to two academic centers. Mult Scler Relat Disord. 2019;30:51–6.

Article  PubMed  Google Scholar 

Kelly SB, et al. Multiple sclerosis, from referral to confirmed diagnosis: an audit of clinical practice. Mult Scler J. 2011;17(8):1017–21.

Article  CAS  Google Scholar 

Thompson AJ, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162–73.

Article  PubMed  Google Scholar 

Masjuan J, Alvarez-Cermeno JC, Garcia-Barragan N, Diaz-Sanchez M, Espino M, Sadaba MC, et al. Clinically isolated syndromes: a new oligoclonal band test accurately predicts conversion to MS. Neurology. 2006;66(4):576e8.

Article  Google Scholar 

Tricco AC, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018;169(7):467–73.

Article  PubMed  Google Scholar 

Novakova L, et al. Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis. J Neurochem. 2017;141(2):296–304.

Article  CAS  PubMed  Google Scholar 

Disanto G, et al. Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis. Ann Neurol. 2017;81(6):857–70.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Edwards KR, et al. Neurofilament light chain as an indicator of exacerbation prior to clinical symptoms in multiple sclerosis. Mult Scler Relat Disord. 2019;31:59–61.

Article  PubMed  Google Scholar 

Delcoigne B, et al. Blood neurofilament light levels segregate treatment effects in multiple sclerosis. Neurology. 2020;94(11):e1201.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kuhle J, et al. Blood neurofilament light chain as a biomarker of MS disease activity and treatment response. Neurology. 2019;92(10):e1007–15.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Quanterix Granted Breakthrough Device Designation from US FDA for NfL Test for Multiple Sclerosis. 2022: quanterix.com. https://www.quanterix.com/press-releases/quanterix-granted-breakthrough-device-designation-from-us-fda-for-nfl-test-for-multiple-sclerosis/

Teunissen CE, et al. Combination of CSF <em>N</em>-acetylaspartate and neurofilaments in multiple sclerosis. Neurology. 2009;72(15):1322.

Article  CAS  PubMed  Google Scholar 

Dalla Costa G, et al. Prognostic value of serum neurofilaments in patients with clinically isolated syndromes. Neurology. 2019;92(7):e733.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Olesen MN, et al. Cerebrospinal fluid biomarkers for predicting development of multiple sclerosis in acute optic neuritis: a population-based prospective cohort study. J Neuroinflammation. 2019;16(1):59.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bjornevik K, et al. Serum Neurofilament Light Chain Levels in Patients With Presymptomatic Multiple Sclerosis. JAMA Neurol. 2020;77(1):58–64.

Article  PubMed  Google Scholar 

Bjornevik K, et al. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science. 2022;375(6578):296–301.

Article  CAS  PubMed  Google Scholar 

Schneider R, et al. Plasma Neurofilament light levels are increased in people with Radiologically Isolated Syndrome (P1–1.Virtual). Neurology. 2022;98(18 Supplement):2084.

Google Scholar 

Matute-Blanch C, et al. Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome. Brain. 2018;141(4):1085–93.

Article  PubMed  Google Scholar 

Bridel C, et al. Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis. JAMA Neurol. 2019;76(9):1035–48.

Article  PubMed  PubMed Central  Google Scholar 

Eng LF, et al. An acidic protein isolated from fibrous astrocytes. Brain Res. 1971;28(2):351–4.

Article  CAS  PubMed  Google Scholar 

Probert F, et al. Determination of CSF GFAP, CCN5, and vWF Levels Enhances the Diagnostic Accuracy of Clinically Defined MS From Non-MS Patients With CSF Oligoclonal Bands. Front Immunol. 2022;12.

Högel H, et al. Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity. Mult Scler J. 2018;26(2):210–9.

Article  Google Scholar 

Abdelhak A, et al. Serum GFAP as a biomarker for disease severity in multiple sclerosis. Sci Rep. 2018;8(1):14798.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Niiranen M, et al. Serum GFAP and NfL levels in benign relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2021;56:103280.

Article  CAS  PubMed  Google Scholar 

Sun M, et al. A candidate biomarker of glial fibrillary acidic protein in CSF and blood in differentiating multiple sclerosis and its subtypes: A systematic review and meta- analysis. Mult Scler Relat Disord. 2021;51:102870.

Article  CAS  PubMed  Google Scholar 

Momtazmanesh S, et al. Neuronal and glial CSF biomarkers in multiple sclerosis: a systematic review and meta-analysis. Rev Neurosci. 2021;32(6):573–95.

Article  CAS  PubMed  Google Scholar 

Abdelhak A, et al. Blood GFAP as an emerging biomarker in brain and spinal cord disorders. Nat Rev Neurol. 2022;18(3):158–72.

Article  CAS  PubMed  Google Scholar 

Bracco F, et al. Free light chains in the CSF in multiple sclerosis. J Neurol. 1987;234(5):303–7.

Article  CAS  PubMed  Google Scholar 

Kricka LJ, Park JY. Assay Principles in Clinical Pathology. In: McManus LM, Mitchell RN, editors. Pathobiology of Human Disease. San Diego: Academic Press; 2014. p. 3207–21.

Chapter  Google Scholar 

Leurs CE, et al. Kappa free light chains is a valid tool in the diagnostics of MS: A large multicenter study. Mult Scler J. 2019;26(8):912–23.

Article  Google Scholar 

Gaetani L, et al. Cerebrospinal fluid free light chains compared to oligoclonal bands as biomarkers in multiple sclerosis. J Neuroimmunol. 2020;339:577108.

Article  CAS  PubMed  Google Scholar 

Altinier S, et al. Free light chains in cerebrospinal fluid of multiple sclerosis patients negative for IgG oligoclonal bands. Clin Chim Acta. 2019;496:117–20.

Article  CAS  PubMed  Google Scholar 

Christiansen M, et al. Cerebrospinal fluid free kappa light chains and kappa index perform equal to oligoclonal bands in the diagnosis of multiple sclerosis. Clin Chem Lab Med. 2018;57(2):210–20.

Article  PubMed  Google Scholar 

Gurtner KM, et al. CSF free light chain identification of demyelinating disease: comparison with oligoclonal banding and other CSF indexes. Clin Chem Lab Med. 2018;56(7):1071–80.

Article  CAS  PubMed  Google Scholar 

Presslauer S, et al. Kappa Free Light Chains: Diagnostic and Prognostic Relevance in MS and CIS. PLoS One. 2014;9(2):e89945.

Article  PubMed  PubMed Central  Google Scholar 

Sanz Diaz CT, et al. Evaluation of Kappa Index as a Tool in the Diagnosis of Multiple Sclerosis: Implementation in Routine Screening Procedure. Front Neurol. 2021;12:676527–676527.

Article  PubMed  PubMed Central  Google Scholar 

Crespi I, et al. Combined use of Kappa Free Light Chain Index and Isoelectrofocusing of Cerebro-Spinal Fluid in Diagnosing Multiple Sclerosis: Performances and Costs. Clin Lab. 2017;63(3):551–9.

CAS  PubMed  Google Scholar 

Cavalla P, et al. Kappa free light chains index in the differential diagnosis of Multiple Sclerosis from Neuromyelitis optica spectrum disorders and other immune-mediated central nervous system disorders. J Neuroimmunol. 2020;339:577122.

Article  CAS  PubMed  Google Scholar 

Konen FF, et al. The Increasing Role of Kappa Free Light Chains in the Diagnosis of Multiple Sclerosis. Cells. 2021;10(11):3056.

Saadeh RS, et al. CSF Kappa Free Light Chains: Cutoff Validation for Diagnosing Multiple Sclerosis. Mayo Clin Proc. 2022;97(4):738–51. Along with NfL, this is the MS biomarker most likely to be clinically relevant to readers now and is available as a commercial test.